strong>Amarna Therapeutics BV, of Leiden, the Netherlands, said it entered a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed) for the development of immunotherapies against acute lymphoblastic leukemia (ALL), obesity, type 2 diabetes and atherosclerotic cardiovascular disease.